Description
CJC-1295 no DAC + Ipamorelin Research Blend
CJC-1295 no DAC (Modified GRF 1-29) and Ipamorelin represent two of the most studied peptides in neuroendocrine research. Together they engage complementary signaling pathways — giving researchers a well-documented model for investigating coordinated receptor activity across two distinct but synergistic systems.
This dual-pathway approach has generated significant interest because the two compounds engage different signaling cascades while producing complementary downstream effects. For researchers studying neuroendocrine signaling, the combination provides a robust model for exploring how two receptor systems coordinate.
Blend Composition
- CJC-1295 no DAC: 5mg — Modified GRF 1-29 for receptor binding research
- Ipamorelin: 5mg — Selective peptide for complementary receptor signaling studies
Scientific Profile
- Total Content: 10mg (5mg + 5mg blend)
Key Research Areas
- Neuroendocrine Research: Studied for coordinated dual-receptor signaling patterns in preclinical models
- Endocrine Signaling: Dual-receptor engagement for studying coordinated signaling and receptor crosstalk
- Receptor Selectivity: Ipamorelin is widely studied for its high specificity to its target receptor with minimal off-target effects
- Research Design: Short-acting profile supports studies investigating pulsatile signaling patterns
Quality & Testing
Every vial is independently tested at a US-accredited lab. HPLC for purity. Mass spec for identity. Endotoxin testing included. Your Certificate of Analysis ships with your order — not buried on a webpage, right there in the box.
Storage
- Lyophilized Powder: Store at -20°C or below for optimal stability
- Prepared Solution: Refrigerate at 2-8°C. Best results within 30 days of preparation
⚠ FOR RESEARCH USE ONLY. NOT INTENDED FOR HUMAN OR VETERINARY CONSUMPTION.
